- Previous Close
2.0400 - Open
2.0800 - Bid 2.2400 x --
- Ask 2.2800 x --
- Day's Range
2.0600 - 2.0800 - 52 Week Range
0.8450 - 9.5200 - Volume
915 - Avg. Volume
450 - Market Cap (intraday)
52.491M - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
-- - EPS (TTM)
-3.9400 - Earnings Date Feb 12, 2025 - Feb 17, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
www.outlooktherapeutics.comRecent News: 41O.F
View MorePerformance Overview: 41O.F
Trailing total returns as of 1/10/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 41O.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 41O.F
View MoreValuation Measures
Market Cap
57.32M
Enterprise Value
71.71M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-83.69%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-94.05M
Diluted EPS (ttm)
-3.9400
Balance Sheet and Cash Flow
Total Cash (mrq)
32.02M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-43.59M